In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, and potential adverse effects and recommended management strategies for the agent.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
